TY - JOUR
T1 - False-positive pathology
T2 - improving reproducibility with the next generation of pathologists
AU - Mazer, Benjamin L.
AU - Homer, Robert J.
AU - Rimm, David L.
N1 - Funding Information:
Conflict of interest DLR discloses the following: He serves as a consultant, advisor and/or serves on a scientific advisory board for Amgen, Astra Zeneca, Agendia, Biocept, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, InVicro/Konica Minolta, Merck, NanoString, Perkin Elmer, PAIGE.AI, and Ultivue. He holds equity in PixelGear. His research lab has funding from Astra Zeneca, Cepheid, Navigate/Novartis, NextCure, Lilly, Ultivue, and Perkin Elmer/Akoya fund. The remaining authors declare that they have no conflict of interest.
Publisher Copyright:
© 2019, United States & Canadian Academy of Pathology.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - The external validity of the scientific literature has recently come into question, popularly referred to as the “reproducibility crisis.” It is now generally acknowledged that too many false positive or non-reproducible results are being published throughout the biomedical and social science literature due to misaligned incentives and poor methodology. Pathology is likely no exception to this problem, and may be especially prone to false positives due to common observational methodologies used in our research. Spurious findings in pathology contribute inefficiency to the scientific literature and detrimentally influence patient care. In particular, false positives in pathology affect patients through biomarker development, prognostic classification, and cancer overdiagnosis. We discuss possible sources of non-reproducible pathology studies and describe practical ways our field can improve research habits, especially among trainees.
AB - The external validity of the scientific literature has recently come into question, popularly referred to as the “reproducibility crisis.” It is now generally acknowledged that too many false positive or non-reproducible results are being published throughout the biomedical and social science literature due to misaligned incentives and poor methodology. Pathology is likely no exception to this problem, and may be especially prone to false positives due to common observational methodologies used in our research. Spurious findings in pathology contribute inefficiency to the scientific literature and detrimentally influence patient care. In particular, false positives in pathology affect patients through biomarker development, prognostic classification, and cancer overdiagnosis. We discuss possible sources of non-reproducible pathology studies and describe practical ways our field can improve research habits, especially among trainees.
UR - http://www.scopus.com/inward/record.url?scp=85064955840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064955840&partnerID=8YFLogxK
U2 - 10.1038/s41374-019-0257-2
DO - 10.1038/s41374-019-0257-2
M3 - Editorial
C2 - 31019290
AN - SCOPUS:85064955840
SN - 0023-6837
VL - 99
SP - 1260
EP - 1265
JO - Laboratory Investigation
JF - Laboratory Investigation
IS - 9
ER -